CannabisNewsBreaks – Lexaria Bioscience Corp. (C
Post# of 721
(Total Views: 297)
Posted On: 11/01/2019 4:49:57 PM
CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Proprietary Drug-Delivery System Featured in Peer-Reviewed Medical Journal
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced that results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published in the peer-reviewed medical journal Advances in Therapy. (http://cnw.fm/s1Ue7). An article discussing the company reads, “In its report, Advances in Therapy also referenced a second study published recently by a separate group of researchers that evaluated a comparable CBD dose with bioabsorption findings representative of the cannabinoid-edibles industry sector in general. The results indicate that the rate of bioabsorption of the CBD from the competitive 100 mg formulation was virtually nondetectable within 30 minutes of administration, whereas the TurboCBD 90 mg dose delivered as much drug at 30 minutes as the competitor formulation required nearly 2.5 hours to achieve.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced that results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published in the peer-reviewed medical journal Advances in Therapy. (http://cnw.fm/s1Ue7). An article discussing the company reads, “In its report, Advances in Therapy also referenced a second study published recently by a separate group of researchers that evaluated a comparable CBD dose with bioabsorption findings representative of the cannabinoid-edibles industry sector in general. The results indicate that the rate of bioabsorption of the CBD from the competitive 100 mg formulation was virtually nondetectable within 30 minutes of administration, whereas the TurboCBD 90 mg dose delivered as much drug at 30 minutes as the competitor formulation required nearly 2.5 hours to achieve.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼